PTC Therapeutics $PTCT got hammered on Monday after the FDA denied its appeal of Refuse to File Letter it received in February regarding its New Drug Application (NDA)seeking approval of Translarna (ataluren) for the treatment of non-sense mutation Duchenne Muscular Dystrophy (nmDMD). �Refuse to File� refers to application was incomplete to make any review. The dug-maker now plans to appeal to the next supervisory level in the agency. It believes that it should also be given the same chance for an advisory committee review that was given to Sarepta Therapeutics� $SRPT eteplirsen.